Published in Clin Sci (Lond) on March 01, 1995
Fetal macrosomia related to maternal poorly controlled type 1 diabetes strongly impairs serum lipoprotein concentrations and composition. J Clin Pathol (2000) 1.48
1H-NMR-based metabolic profiling of maternal and umbilical cord blood indicates altered materno-foetal nutrient exchange in preterm infants. PLoS One (2012) 0.90
Maternal and pregnancy related predictors of cardiometabolic traits in newborns. PLoS One (2013) 0.79
Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol (2016) 0.76
Sex-Specific Parental Effects on Offspring Lipid Levels. J Am Heart Assoc (2015) 0.76
Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. Eur J Clin Pharmacol (2011) 0.75
Congenital anterior abdominal wall defects in England and Wales 1987-93: retrospective analysis of OPCS data. BMJ (1996) 6.97
Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet (1995) 5.79
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta-analysis. Ultrasound Obstet Gynecol (2013) 3.28
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet (1999) 2.75
Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol (1990) 2.74
Cloning of the afl-2 gene involved in aflatoxin biosynthesis from Aspergillus flavus. Appl Environ Microbiol (1993) 2.71
Cloning of the Aspergillus parasiticus apa-2 gene associated with the regulation of aflatoxin biosynthesis. Appl Environ Microbiol (1993) 2.57
Molecular characterization of aflR, a regulatory locus for aflatoxin biosynthesis. Appl Environ Microbiol (1994) 2.56
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
The premenstrual syndrome: a review of the present status of therapy. Drugs (1982) 2.52
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis (1993) 2.48
Comparative mapping of aflatoxin pathway gene clusters in Aspergillus parasiticus and Aspergillus flavus. Appl Environ Microbiol (1995) 2.33
Identification of O-methylsterigmatocystin as an aflatoxin B1 and G1 precursor in Aspergillus parasiticus. Appl Environ Microbiol (1987) 2.24
Cloning and characterization of a cDNA from Aspergillus parasiticus encoding an O-methyltransferase involved in aflatoxin biosynthesis. Appl Environ Microbiol (1993) 2.10
Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev (2004) 2.05
Dilatation and curettage in patients with cervical polyps: a retrospective analysis. Br J Obstet Gynaecol (1995) 2.01
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet (2000) 1.98
Prevention of macrovascular disease: absolute proof or absolute risk? Diabet Med (1995) 1.93
Association and prediction of amniotic fluid measurements for adverse pregnancy outcome: systematic review and meta-analysis. BJOG (2014) 1.91
Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis. Ultrasound Obstet Gynecol (2011) 1.85
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
Appearance of enzyme activities catalyzing conversion of sterigmatocystin to aflatoxin B1 in late-growth-phase Aspergillus parasiticus cultures. Appl Environ Microbiol (1987) 1.79
A randomised prospective study comparing the new vacuum extractor policy with forceps delivery. Br J Obstet Gynaecol (1993) 1.77
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol (2001) 1.76
Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract (2008) 1.75
Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet (1992) 1.74
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology (Oxford) (2003) 1.72
Increased expression of Aspergillus parasiticus aflR, encoding a sequence-specific DNA-binding protein, relieves nitrate inhibition of aflatoxin biosynthesis. Appl Environ Microbiol (1995) 1.66
Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation (2001) 1.59
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis (2005) 1.55
Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest (1982) 1.53
A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev (2008) 1.53
Purification of a 40-kilodalton methyltransferase active in the aflatoxin biosynthetic pathway. Appl Environ Microbiol (1993) 1.52
Premenstrual syndrome. Br Med J (Clin Res Ed) (1986) 1.52
Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest (2002) 1.52
Trichobezoar obstructing the terminal ileum. Trop Doct (2002) 1.51
Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol (1979) 1.51
Averufanin is an aflatoxin B1 precursor between averantin and averufin in the biosynthetic pathway. Appl Environ Microbiol (1987) 1.49
HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis (1995) 1.48
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol (1996) 1.48
The Aspergillus parasiticus polyketide synthase gene pksA, a homolog of Aspergillus nidulans wA, is required for aflatoxin B1 biosynthesis. Mol Gen Genet (1995) 1.46
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.44
Intrapartum fetal cerebral near infrared spectroscopy: apparent change in oxygenation demonstrated in a non viable fetus. Br J Obstet Gynaecol (1995) 1.43
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med (2007) 1.42
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant (1993) 1.42
Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet (1988) 1.42
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol (1995) 1.40
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett (1998) 1.40
The future of gene therapy in obstetrics and gynaecology. Hosp Med (1998) 1.39
ST-waveform analysis of the fetal electrocardiogram could reduce fetal blood sampling. Br J Obstet Gynaecol (1992) 1.39
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39
The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) (1998) 1.38
Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease. BMJ (1993) 1.38
Determination of total menstrual blood loss. Fertil Steril (2001) 1.37
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
Sequence variability in homologs of the aflatoxin pathway gene aflR distinguishes species in Aspergillus section Flavi. Appl Environ Microbiol (1995) 1.32
Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis (1990) 1.32
Structure and function of fas-1A, a gene encoding a putative fatty acid synthetase directly involved in aflatoxin biosynthesis in Aspergillus parasiticus. Appl Environ Microbiol (1996) 1.28
Lipid peroxidative damage on pyrethroid exposure and alterations in antioxidant status in rat erythrocytes: a possible involvement of reactive oxygen species. Toxicol Lett (1999) 1.27
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol (1997) 1.27
Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia (2009) 1.26
A systematic review of the accuracy of first-trimester ultrasound examination for detecting major congenital heart disease. Ultrasound Obstet Gynecol (2006) 1.25
Characterization of the Aspergillus parasiticus niaD and niiA gene cluster. Curr Genet (1996) 1.24
Approach to the management of premenstrual syndrome. Clin Obstet Gynecol (1987) 1.24
Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab (2001) 1.21
Evidence for de novo synthesis of an aflatoxin pathway methyltransferase near the cessation of active growth and the onset of aflatoxin biosynthesis in Aspergillus parasiticus mycelia. Can J Microbiol (1990) 1.20
Human serum paraoxonase. Gen Pharmacol (1998) 1.20
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med (2008) 1.20
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. J Clin Pathol (1992) 1.19
Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol Res (1998) 1.19
11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum Reprod (1998) 1.18
Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.18
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart (2004) 1.17
Molecular characterization of an Aspergillus parasiticus dehydrogenase gene, norA, located on the aflatoxin biosynthesis gene cluster. Appl Environ Microbiol (1996) 1.17
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J (1993) 1.16
Human cholesterol metabolism and therapeutic molecules. Exp Physiol (2008) 1.15
A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer (2006) 1.15
Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis (1991) 1.14
stcS, a putative P-450 monooxygenase, is required for the conversion of versicolorin A to sterigmatocystin in Aspergillus nidulans. Appl Environ Microbiol (1995) 1.13
Characterization of aflJ, a gene required for conversion of pathway intermediates to aflatoxin. Appl Environ Microbiol (1998) 1.12
Effect of pectin on serum lipids and lipoproteins, whole-gut transit-time, and stool weight. Lancet (1976) 1.12
Systematic review of the effectiveness of antenatal intervention for the treatment of congenital lower urinary tract obstruction. BJOG (2010) 1.12
Adenosine cyclic 3',5'-monophosphate dependent protein kinase: a new fluorescence displacement titration technique for characterizing the nucleotide binding site on the catalytic subunit. Biochemistry (1983) 1.11
Characterization of the critical amino acids of an Aspergillus parasiticus cytochrome P-450 monooxygenase encoded by ordA that is involved in the biosynthesis of aflatoxins B1, G1, B2, and G2. Appl Environ Microbiol (1998) 1.11
Clinical value of apolipoprotein measurement. Ann Clin Biochem (1991) 1.10
Congenital malformations of the diaphragm: findings of the West Midlands Congenital Anomaly Register 1995 to 2000. Prenat Diagn (2004) 1.10
Placental iodothyronine deiodinase expression in normal and growth-restricted human pregnancies. J Clin Endocrinol Metab (2003) 1.09
Protective effect of vitamin E in dimethoate and malathion induced oxidative stress in rat erythrocytes. J Nutr Biochem (2001) 1.09